PP405 for hair loss: what the 2026 trial data actually shows (and when it might reach the UK)

By Amina Mughal

Published: Friday, June 15, 2026

TL;DR — key facts

PP405 is a topical drug by Pelage Pharmaceuticals entering Phase 3 trials in 2026, backed by $120M from Google Ventures.
Phase 2a showed 31% of men with advanced thinning achieved >20% hair density increase vs 0% placebo — no systemic side effects.
It works via MPC inhibition (a metabolic switch), not hormones — making it one of the only pipeline treatments designed for both men and women from the start.

UK availability: estimated 2028–2030 at the earliest.

31%

of men saw >20% density increase (Phase 2a)

$120M

Series B — Google Ventures + ARCH

2028–30

Earliest realistic UK availability

Title

What is PP405?

Developed at UCLA and commercialised by Pelage Pharmaceuticals, PP405 is a once-daily topical small-molecule drug — not a peptide, not a biologic. It enters Phase 3 trials in 2026 with $120M in Series B backing from Google Ventures and ARCH Venture Partners, one of the largest fundraises ever seen in the hair loss space...

Title

How does PP405 work? (the MPC mechanism explained)

The problem: follicles go dormant, not dead

In androgenetic alopecia, follicles miniaturise and enter a prolonged dormant state — they're not destroyed. This distinction matters because PP405 only works where follicles remain viable...

The metabolic switch — MPC inhibition

PP405 blocks the mitochondrial pyruvate carrier inside follicle stem cells, shifting how those cells generate energy. This metabolic change signals the follicle to exit dormancy and re-enter the anagen (growth) phase — entirely independent of DHT or androgen pathways...

Treatment comparison

Treatment	How it works	Women	Hormonal	Status
PP405 Pelage Pharma	Blocks MPC in follicle stem cells — metabolic switch reactivates dormant follicles. No androgen involvement.	✓ Both sexes	✓ No	Phase 3
Minoxidil Topical & oral	Vasodilator — widens blood vessels around active follicles. Doesn't reactivate dormant ones.	✓ Licensed	✓ No	Licensed
Finasteride 1mg oral	Blocks 5α-reductase enzyme, reducing DHT. Slows miniaturisation but doesn't regrow lost hair.	✗ Men only	✗ Yes	Licensed
Dutasteride Off-label	Dual 5α-reductase inhibitor — stronger DHT suppression than finasteride. Off-label for hair loss.	✗ Men only	✗ Yes	Off-label

PP405 Phase 3 trials

How it works

MPC inhibition — reactivates dormant follicle stem cells without hormones

Women

✓ Trialled in both sexes

Hormonal

✓ Non-hormonal

Minoxidil Licensed

How it works

Vasodilator — improves blood supply to active follicles

Women

✓ Yes — licensed

Hormonal

✓ Non-hormonal

Finasteride Men only

How it works

Blocks DHT via 5α-reductase — slows hair loss progression

Women

✗ Not MHRA licensed

Hormonal

✗ Hormonal

Dutasteride Off-label

How it works

Stronger dual DHT blocker than finasteride — off-label for hair loss

Women

✗ Not licensed

Hormonal

✗ Hormonal

What does the clinical evidence actually show?

Phase 2a results (announced June 2025, presented AAD 2026)

The randomised, double-masked, vehicle-controlled trial met its primary safety endpoints. No systemic absorption was detected. In exploratory efficacy readings — specifically in men with more advanced hair loss — 31% achieved greater than 20% increase in hair density at week 8 (four weeks after completing the dosing period), versus 0% in the placebo group. New terminal hair was observed growing from follicular units where no visible hair had previously been present...

"A well-tolerated, topically delivered therapy that shows measurable biological activity this early is rare." — Dr. Arash Mostaghimi, Vice Chair of Clinical Trials, Brigham and Women's Hospital

What the data doesn't yet tell us

The efficacy finding was observed in a subgroup, not uniformly across all participants. Follow-up was 8–12 weeks — long-term durability is unknown. The full open-label extension dataset is expected at a future medical conference...

Title

UK availability and regulatory timeline

2023–2024

Phase 1 — safety confirmed

No systemic absorption. Ki67 follicle activation markers significantly elevated.

June 2025

Phase 2a results announced

31% density increase in subgroup. $120M Series B raised. Presented at AAD Denver 2026.

2026 — now

Phase 3 trials initiated

Larger pivotal study in men and women. UK sites may open — check NIHR Be Part of Research

2027–2028

Phase 3 results expected

If positive → MHRA submission. Review typically takes 12–18 months.

2028–2030

Earliest realistic UK availability

Assumes positive Phase 3, successful MHRA review, and manufacturing scale-up.

Title

Should I wait for PP405 or start treatment now?

Start treatment now

Moderate-to-significant loss

Concerned about continued progression

Want proven results now

Consider: oral minoxidil, finasteride, GHK-Cu

Monitor PP405

Early-stage loss only

Specifically want non-hormonal

Willing to track trial progress

Sign up: pelagepharma.com/trials

Frequently asked questions

What is PP405 and how does it work?

PP405 is a topical small-molecule drug developed by Pelage Pharmaceuticals that reactivates dormant hair follicle stem cells by inhibiting the mitochondrial pyruvate carrier (MPC), triggering a metabolic shift that restarts the hair growth cycle without affecting hormones.

What did the PP405 Phase 2a trial results show?

31% of men with more advanced hair loss achieved greater than 20% increase in hair density at week 8, versus 0% in the placebo group. No systemic absorption was detected. The trial was randomised, double-masked, and vehicle-controlled.

Can women use PP405 for hair loss?

PP405 is being trialled in both men and women — unusually, it was designed for both sexes from the outset. This makes it potentially significant for women with female-pattern hair loss, who have very limited licensed options (finasteride is not MHRA-licensed for women).

When will PP405 be available in the UK?

Realistically, 2028–2030 at the earliest, assuming positive Phase 3 results, a successful MHRA review (typically 12–18 months), and manufacturing scale-up. There is no guarantee the drug will reach market.

Are products sold online as "PP405" real?

No. PP405 is an investigational drug not available for purchase anywhere. Any product marketed as PP405 is not the real compound. Do not buy these — they are unverified and potentially unsafe.

Is PP405 the same as a peptide for hair loss?

No. PP405 is a small-molecule drug (an MPC inhibitor), not a peptide and not a biologic. It is sometimes grouped with hair growth peptides in casual coverage, but mechanistically it belongs to a different category entirely.

Hurry up! Sale 20%. Sale ends in:

Days

Hrs

Mins

Secs

Nourish Roots

Volumize Locks

Healthy Scalp

Hair Growth

Check Availability

14-day money back guarantee

Experience The Power From Nature

Since day one, our mission has been to help you feel your best with clean, effective supplements made from 100% pure ingredients. No nasties, no confusion, just plant-powered health that works. And with your feedback, we're always leaning and improving to keep you energised and confident daily.

Shop Our Supplements

14-Day Easy Returns And Exchanges